Literature DB >> 15361549

Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of extracellular signal-regulated kinases 1/2.

Louis Gendron1, Amélie Perron, Marcel Daniel Payet, Nicole Gallo-Payet, Philippe Sarret, Alain Beaudet.   

Abstract

The role and signaling properties of the low-affinity neurotensin receptor (NTS2) are still controversial. In particular, it is unclear whether neurotensin acts as an agonist, inverse agonist, or antagonist at this site. In view of the growing evidence for a role of NTS2 in antinociception, the elucidation of the pharmacological and coupling properties of this receptor is particularly critical. In the present study, we demonstrate that in Chinese hamster ovary (CHO) cells expressing the rat NTS2 receptor, neurotensin (NT), levocabastine, neuromedin N, and the high-affinity NT receptor antagonist SR48692 [2-[[1-(-7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid] all bind to and activate the NTS2 receptor. This activation is followed by ligand-induced internalization of receptor-ligand complexes, as evidenced by confocal microscopy using a fluorescent NT analog. All compounds tested produced a rapid and sustained activation of extracellular signal-regulated kinases 1/2 (ERK1/2) but were without specific effect on Ca(2+) mobilization. The agonist-induced activation of ERK1/2 was completely abolished by preincubation of the cells with the endocytosis inhibitors phenylarsine oxide and monodansylcadaverine as well as overexpression of a dominant-negative mutant of dynamin 1 (DynK44A), indicating that receptor internalization was required for ERK1/2 activation. NTS2-induced activation of ERK1/2 was not species-specific, because the same agonistic effects of NT and analogs were observed in CHO cells transfected with the human NTS2 receptor. In conclusion, this study demonstrates that NTS2 is a bona fide NT receptor and that activation of this receptor by NT or NT analogs results in an internalization-dependent activation of the ERK1/2 signaling cascade.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15361549     DOI: 10.1124/mol.104.002303

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

2.  Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference.

Authors:  Klara Felszeghy; José Manuel Espinosa; Hélène Scarna; Anne Bérod; William Rostène; Didier Pélaprat
Journal:  Neuropsychopharmacology       Date:  2007-03-14       Impact factor: 7.853

3.  The amide linker in nonpeptide neurotensin receptor ligands plays a key role in calcium signaling at the neurotensin receptor type 2.

Authors:  James B Thomas; Angela M Giddings; Srinivas Olepu; Robert W Wiethe; Keith R Warner; Philippe Sarret; Jean-Michel Longpre; Scott P Runyon; Brian P Gilmour
Journal:  Bioorg Med Chem Lett       Date:  2015-04-03       Impact factor: 2.823

4.  The Internalization of Neurotensin by the Low-Affinity Neurotensin Receptors (NTSR2 and vNTSR2) Activates ERK 1/2 in Glioma Cells and Allows Neurotensin-Polyplex Transfection of tGAS1.

Authors:  Alberto E Ayala-Sarmiento; Daniel Martinez-Fong; José Segovia
Journal:  Cell Mol Neurobiol       Date:  2015-03-14       Impact factor: 5.046

5.  Identification of N-{[6-chloro-4-(2,6-dimethoxyphenyl)quinazolin-2-yl]carbonyl}-l-leucine (NTRC-808), a novel nonpeptide chemotype selective for the neurotensin receptor type 2.

Authors:  James B Thomas; Angela M Giddings; Srinivas Olepu; Robert W Wiethe; Danni L Harris; Sanju Narayanan; Keith R Warner; Philippe Sarret; Jean-Michel Longpre; Scott P Runyon; Brian P Gilmour
Journal:  Bioorg Med Chem Lett       Date:  2014-11-24       Impact factor: 2.823

6.  NT79: A novel neurotensin analog with selective behavioral effects.

Authors:  Mona Boules; Yanqi Liang; Siobhan Briody; Tomofumi Miura; Irfan Fauq; Alfredo Oliveros; Mina Wilson; Shaheen Khaniyev; Katrina Williams; Zhimin Li; Yanfei Qi; Michael Katovich; Elliott Richelson
Journal:  Brain Res       Date:  2009-10-27       Impact factor: 3.252

Review 7.  NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.

Authors:  Daniel Martinez-Fong; Michael J Bannon; Louis-Eric Trudeau; Juan A Gonzalez-Barrios; Martha L Arango-Rodriguez; Nancy G Hernandez-Chan; David Reyes-Corona; Juan Armendáriz-Borunda; Ivan Navarro-Quiroga
Journal:  Nanomedicine       Date:  2012-03-07       Impact factor: 5.307

8.  Neurotensin is an anti-thermogenic peptide produced by lymphatic endothelial cells.

Authors:  Jin Li; Erwei Li; Rafael S Czepielewski; Jingyi Chi; Xiao Guo; Yong-Hyun Han; Daqing Wang; Luhong Wang; Bo Hu; Brian Dawes; Christopher Jacobs; Danielle Tenen; Samuel J Lin; Bernard Lee; Donald Morris; Adam Tobias; Gwendalyn J Randolph; Paul Cohen; Linus Tsai; Evan D Rosen
Journal:  Cell Metab       Date:  2021-05-25       Impact factor: 31.373

9.  Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy.

Authors:  Zherui Wu; Daniel Martinez-Fong; Jean Trédaniel; Patricia Forgez
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-17       Impact factor: 5.555

10.  Neurotensin-produced antinociception in the rostral ventromedial medulla is partially mediated by spinal cord norepinephrine.

Authors:  A V Buhler; H K Proudfit; G F Gebhart
Journal:  Pain       Date:  2007-07-30       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.